MARKET

RXRX

RXRX

Recursion Pharmaceuticals, Inc.
NASDAQ
3.535
-0.175
-4.72%
Opening 12:34 02/12 EST
OPEN
3.730
PREV CLOSE
3.710
HIGH
3.750
LOW
3.510
VOLUME
10.10M
TURNOVER
--
52 WEEK HIGH
12.36
52 WEEK LOW
3.510
MARKET CAP
1.84B
P/E (TTM)
-1.9538
1D
5D
1M
3M
1Y
5Y
1D
Most shorted large-cap stocks in January
Seeking Alpha · 6h ago
Recursion Pharmaceuticals reports grant of inducement awards
TipRanks · 7h ago
Recursion Pharmaceuticals Grants Inducement RSUs to 17 New Employees
Reuters · 7h ago
RECURSION REPORTS GRANT OF INDUCEMENT AWARDS AS PERMITTED BY THE NASDAQ LISTING RULES
Reuters · 7h ago
A Look At Recursion Pharmaceuticals (RXRX) Valuation After New AI Bioengineering Market Study
Simply Wall St · 2d ago
Weekly Report: what happened at RXRX last week (0202-0206)?
Weekly Report · 3d ago
Is Recursion Pharmaceuticals (RXRX) Pricing Reflect Its Steep Share Price Declines And DCF Outlook
Simply Wall St · 3d ago
This $4 Stock Could Be Your Ticket to Millionaire Status
The Motley Fool · 4d ago
More
About RXRX
Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology and chemistry to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits, scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate silico hypotheses into validated insights and novel chemistry. Its clinical programs in oncology and rare diseases include REC-617, REC-1245, REC-3565 and REC-4539. Its REC-617 is an orally bioavailable, cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced solid tumors. Its REV102 program targets ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), an enzyme implicated in the pathogenesis of HPP.

Webull offers Recursion Pharmaceuticals Inc stock information, including NASDAQ: RXRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RXRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RXRX stock methods without spending real money on the virtual paper trading platform.